C17orf58

Model summary

A human extracellular modulator that uses a netrin-like OB-fold to bind partners with high affinity and anchor within collagen-rich matrices. By assembling and stabilizing pericellular complexes at the cell–matrix interface, it dampens signaling through the TGF-beta receptor pathway, likely by limiting ligand availability, stabilizing inactive receptor states, or promoting receptor complex clearance. Its mechanism is driven by a rigid extracellular binding platform that organizes matrix-associated assemblies to fine-tune signaling thresholds.

Predicted Gene Ontology terms

1. 01

   I begin with the InterPro architecture.

   The C-terminal half of the protein is dominated by IPR008993 (Tissue inhibitor of metalloproteinases-like, OB-fold homologous superfamily, residues 187–339). Within this OB-fold scaffold sits IPR001134 (Netrin domain, residues 193–338), and the same span is annotated as IPR064080 (UPF0450 protein C17orf58-like domain, residues 193–338). This arrangement—an OB-fold core that forms a netrin-like module—creates a compact, disulfide-rich extracellular fold specialized for avid protein–protein interactions and matrix association. The OB-fold/netrin architecture is well-suited for high-affinity binding to extracellular ligands and receptors, and it frequently underlies secreted or pericellular inhibitors and modulators rather than intracellular enzymes.

2. 02

   This OB-fold–netrin module causally supports GO:0005515 protein binding as the molecular function: the fold confers a rigid binding platform that captures extracellular partners with high specificity.

   The absence of catalytic motifs and the presence of a matrix-oriented OB-fold argue that the protein acts through binding and modulation rather than enzymatic turnover.

3. 03

   From this binding-centric mechanism, I infer its role in signaling control.

   The OB-fold/netrin module is classically used to tune pathways at the cell surface and within the extracellular matrix. Such a module can sequester or scaffold components of the TGF-beta pathway, thereby dampening receptor activation and downstream SMAD signaling. This mechanistic logic aligns with GO:0030512 negative regulation of transforming growth factor beta receptor signaling pathway: by binding to matrix-tethered complexes or receptor-associated adaptors, the protein attenuates signal flux through the TGF-beta axis.

4. 04

   The cellular context follows directly from the fold and process.

   OB-fold/netrin architectures are archetypal of secreted/pericellular proteins that embed into or associate with extracellular scaffolds. This supports localization to the GO:0062023 collagen-containing extracellular matrix, where the protein can access and modulate matrix-bound receptors and ligands. A matrix-tethered modulator situated at the cell–matrix interface provides the spatial vantage point necessary to suppress TGF-beta receptor signaling.

5. 05

   Putting these elements together yields a mechanistic hypothesis.

   The OB-fold/netrin core forms a stable extracellular binding hub that anchors within collagen-rich matrices. By docking to matrix components and to receptor–ligand assemblies, it likely reduces the effective activity of TGF-beta receptor complexes—either by limiting ligand availability, stabilizing inactive receptor states, or promoting endocytic clearance. Consequently, it functions as a secreted/pericellular modulator that binds partners to restrain TGF-beta signaling.

6. 06

   From this model, I hypothesize interaction partners that fit the matrix-tethered signaling checkpoint: extracellular TGF-beta ligands and receptor ectodomains at the cell surface; collagen IV and fibronectin as matrix footholds; and pericellular regulators that cooperate with OB-fold modules.

   These associations would collectively position the protein to fine-tune TGF-beta pathway output in the extracellular milieu.